Dernières nouvelles pour Clorox (NYSE:CLX) Stock

Clorox

Since its inception more than 100 years ago, Clorox has grown to play in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just less than 85% of Clorox's sales stem from its home turf.

Clorox Co

Calix Ltd

COLLEXIS HOLDINGS INC by Collexis Holdings, Inc.

Collexis Holdings Inc

As the third-quarter earnings season approaches, Goldman Sachs has issued a note identifying key stock opportunities for investors looking to profit <a href="https://www.benzinga.com/news/earnings/24/10/41255250/banks-gear-up-for-earnings-season-15-top-stock-picks-including-citigroup-morgan-stanley-and-truist">from financial results.</a>
Analyst John Marshall and his team shared their insights on Thursday, highlighting 18 stocks that could benefit from upward earnings revisions and seven stocks likely to face downward revisions.
<h3 class="wp-block-heading">The &#8216;Stock Picker&#8217;s Year&#8217;: 10% Upside In S&amp;P 500</h3>
Goldman Sachs analysts call 2024 "the year of the stock picker," emphasizing the importance of selective investing in a volatile earnings environment.
According to the investment bank&#8217;s latest projections, the average S&amp;P 500 stock could see a 10% upside over the next 12 months. 
"We see relief rally potential," Marshall stated in his note. "Directional positioning in the options market is balanced, a much better set-up than this time last quarter."
The analysts also observed that activity in options markets, both from hedge funds and retail traders, has decreased recently, signaling a "wait-and-see" approach as investors prepare for third-quarter earnings reports and the upcoming U.S. elections.
<h3 class="wp-block-heading">Earnings Season Volatility Remains Elevated</h3>
Goldman Sachs highlighted that single-stock volatility surrounding earnings events remains at a 14-year high. 
This trend, driven by critical market debates on topics like artificial intelligence, interest rates, and the upcoming election, is expected to continue through the remainder of the year.
&#8220;We expect earnings day moves to remain elevated as most of the key debates for the market have winners and losers in the equity space,&#8221; the note added. 
With this heightened volatility, the firm continues to recommend options-based strategies, advising investors to consider buying options ahead of earnings events and selling options between earnings periods to capitalize on price movements.
<h3 class="wp-block-heading">18 Stocks Goldman Sachs Is Bullish On For Third-Quarter Earnings</h3>
Goldman Sachs&#8217; analysts have identified 18 stocks they believe are primed for upside as earnings revisions could be favorable. These stocks span a variety of sectors, from energy and financials to healthcare and technology.
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>Sector</th>
<th>Earnings Date (e)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>)</td>
<td>Discretionary</td>
<td>Nov. 15</td>
</tr>
<tr>
<td>Permian Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PR#NYSE">PR</a>)</td>
<td>Energy</td>
<td>Nov. 7</td>
</tr>
<tr>
<td>Citigroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>)</td>
<td>Financials</td>
<td>Oct. 15</td>
</tr>
<tr>
<td>Synchrony Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYF#NYSE">SYF</a>)</td>
<td>Financials</td>
<td>Oct. 16</td>
</tr>
<tr>
<td>Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)</td>
<td>Healthcare</td>
<td>Oct. 30</td>
</tr>
<tr>
<td>Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>)</td>
<td>Healthcare</td>
<td>Oct. 23</td>
</tr>
<tr>
<td>Merck &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</td>
<td>Healthcare</td>
<td>Oct. 31</td>
</tr>
<tr>
<td>Qiagen NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>)</td>
<td>Healthcare</td>
<td>Oct. 30</td>
</tr>
<tr>
<td>AZEK Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZEK#NYSE">AZEK</a>)</td>
<td>Industrials</td>
<td>Nov. 29</td>
</tr>
<tr>
<td>ADT Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADT#NYSE">ADT</a>)</td>
<td>TMT</td>
<td>Nov. 1</td>
</tr>
<tr>
<td>Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)</td>
<td>TMT</td>
<td>Dec. 6</td>
</tr>
<tr>
<td>Dell Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>)</td>
<td>TMT</td>
<td>Nov. 25</td>
</tr>
<tr>
<td>Klaviyo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>)</td>
<td>TMT</td>
<td>Nov. 7</td>
</tr>
<tr>
<td>Monday.com Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>)</td>
<td>TMT</td>
<td>Nov. 13</td>
</tr>
<tr>
<td>Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</td>
<td>TMT</td>
<td>Nov. 21</td>
</tr>
<tr>
<td>Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>)</td>
<td>TMT</td>
<td>Nov. 29</td>
</tr>
<tr>
<td>Toast Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>)</td>
<td>TMT</td>
<td>Nov. 7</td>
</tr>
<tr>
<td>Sempra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRE#NYSE">SRE</a>)</td>
<td>Utilities</td>
<td>Nov. 4</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">7 Stocks Goldman Sachs Is Bearish On For Third-Quarter Earnings</h3>
In contrast, the investment bank has identified seven stocks that they expect to face downward earnings revisions in the third quarter, advising investors to exercise caution.
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>Sector</th>
<th>Earnings Date (e)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Choice Hotels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHH#NYSE">CHH</a>)</td>
<td>Discretionary</td>
<td>Nov. 7</td>
</tr>
<tr>
<td>Cheniere Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CQP#NYSE">CQP</a>)</td>
<td>Energy</td>
<td>Nov. 1</td>
</tr>
<tr>
<td>Janus Henderson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHG#NYSE">JHG</a>)</td>
<td>Financials</td>
<td>Oct. 31</td>
</tr>
<tr>
<td>LyondellBasell (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>)</td>
<td>Materials</td>
<td>Nov. 1</td>
</tr>
<tr>
<td>Clorox Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>)</td>
<td>Staples</td>
<td>Nov. 1</td>
</tr>
<tr>
<td>Kraft Heinz Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>)</td>
<td>Staples</td>
<td>Oct. 30</td>
</tr>
<tr>
<td>Upstart Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>)</td>
<td>TMT</td>
<td>Nov. 7</td>
</tr>
</tbody>
</table>
</figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41278012/feds-goolsbee-downplays-inflation-uptick-economists-hold-steady-on-november-rate-in">Fed&#8217;s Goolsbee Downplays Inflation Uptick, Economists Hold Steady On November Rate Interest Rate Cut Call</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Earnings

Equities

Large Cap

Mid Cap

Tech

ETFs

AMGN

AVGO

AZEK

DELL

Janus Henderson Group plc Ordinary Shares

KVYO

MNDY

NVDA

QGEN

SNOW

TOST

UPST

18 Stocks To Buy, 7 To Sell This Earnings Season: Goldman Sachs Calls It 'The Year Of The Stock Picker'

Linda Rendle, Chief Executive Officer at Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>), disclosed an insider purchase on October 8, based on a new SEC filing.
What Happened: In a significant move reported in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000021076/000122520824009227//Archives/edgar/data/21076/000122520824009227/0001225208-24-009227-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday, Rendle purchased 32,639 shares of Clorox, demonstrating confidence in the company's growth potential. The total value of the transaction stands at $5,273,483.
Tracking the Wednesday's morning session, Clorox shares are trading at $158.89, showing a down of 0.56%.
<h3>About Clorox</h3>
Since its inception more than 100 years ago, Clorox has grown to play in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just less than 85% of Clorox's sales stem from its home turf.
<h3>Financial Insights: Clorox</h3>
Negative Revenue Trend: Examining Clorox's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately -5.75% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Staples sector.
Interpreting Earnings Metrics:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 46.45%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Clorox's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 1.74.
</li>
</ul>
Debt Management: Clorox's debt-to-equity ratio is below the industry average at 8.85, reflecting a lower dependency on debt financing and a more conservative financial approach.
Insights into Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: Clorox's current Price to Earnings (P/E) ratio of 71.02 is higher than the industry average, indicating that the stock may be overvalued according to market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 2.81 is above industry norms, reflecting an elevated valuation for Clorox's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Clorox's EV/EBITDA ratio of 31.07 exceeds industry averages, indicating a premium valuation in the market
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Activity Matters in Finance</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Essential Transaction Codes Unveiled</h3>
When dissecting transactions, the focal point for <a href="https://www.benzinga.com/money/investing-tools">investors</a> is often those occurring in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000021076">Check Out The Full List Of Clorox's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Insider Trades

Trading Ideas

Chief Executive Officer Of Clorox Purchased $5.27M In Stock

Clorox Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) is scheduled to report its quarterly earnings in early November.
The stock's risk/reward is negative heading into the third-quarter results, according to Goldman Sachs <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58aed4dcb85e9300013bf4da/bonnie-herzog">analyst Bonnie Herzog</a>.
The Clorox Thesis: Herzog reiterated a Sell rating for and price target of $132. 
The company faces easy year-ago comps and made progress in restoring product availability and market share. As a result, expectations have risen, Herzog said in the note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Certain areas remain challenging "due to lack of product availability, heightened competition, purchase cycles and category dynamics." That could require more promotional support.
Recent checks suggest that Clorox's promotions are "well above" the pre-Covid levels in certain categories and the company's two-year trends suggest "a sequential moderation in total sales growth," the analyst stated. "As such, we see an environment of elevated promotions and rising concerns around the health of the consumer to limit the rate of retail inventory pipeline fill, esp. in CLX's Household segment, with some sales likely getting pushed out to FQ2," he further wrote.
There is downside to the current consensus estimates and Clorox's organic sales growth in fiscal 2025 is likely to be back-end loaded, Herzog said.
Price Action: Shares of Clorox had declined by 1.03% to $158.94 at the time of publication on Tuesday.
The company received an upgrade from a <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41127080/clorox-positioned-for-comeback-analyst-predicts-earnings-beats-and-3-year-growth-su">Jefferies analyst who predicted an earnings beat</a>. 
Read More:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40735799/nvidia-beaten-by-clorox-mother-of-all-reports-ahead">Nvidia Beaten By Clorox, Mother Of All Reports Ahead</a></li>
</ul>
Image: Shutterstock

Short Ideas

Reiteration

Analyst Ratings

Movers

This Clorox Analyst Believes There Is Downside To Estimates

Jefferies analyst Kaumil&nbsp;Gajrawala upgraded Clorox Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) to Buy from Hold, raising the price forecast to $187 from $174.
The analyst projects that Clorox will return to its former status as a company delivering peer-leading economic profit growth and returns on capital.
Historically, this performance has warranted a valuation premium of 30% compared to its peers.
According to the analyst, topline growth is already showing signs of improvement, and operating leverage is becoming increasingly attainable.
Clorox has lagged behind its peers in growth reinvestments due to challenges such as COVID, supply chain issues, inflation, and cybersecurity from 2020 to 2024.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41114350/chinese-ev-trio-nio-xpeng-li-auto-surge-higher-in-tuesdays-premarket-whats-going-on" rel="noreferrer noopener">Chinese EV Trio Nio, XPeng, Li Auto Surge Higher In Tuesday's Premarket: What's Going On</a>
However, the analyst notes that this is beginning to change. With ERP deployments primarily expensed and a U.S. rollout expected by fiscal fourth quarter, the company aims to streamline its innovation pipeline, enhance RGM capabilities, and drive SG&amp;A leverage. The analyst forecasts that these changes will lead to earnings beats.
The analyst projects Clorox to achieve a three-year organic sales compound annual growth rate (CAGR) of +3.6% through fiscal 2028. According to the analyst, the company is well-positioned to meet its target of +3-5%, driven by anticipated organic sales growth of +3% in the U.S. and +5.5% internationally, with U.S. sales expected to return to fiscal 2023 levels by fiscal 2025.
Early indicators are promising, as trade spend increases have shown positive results, the analyst adds.
Price Action: CLX shares are trading higher by 0.96% to $164.47 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/41082193/teslas-chinese-rival-nio-snags-1-9b-investment-from-parent-strategic-investors-as-it-forays-into" target="_blank" rel="noreferrer noopener">Tesla's Chinese Rival Nio Snags $1.9B Investment From Parent, Strategic Investors As It Forays Into Mass Market</a></li>
</ul>

Upgrades

Price Target

General

Clorox Positioned For Comeback: Analyst Predicts Earnings Beats And 3-Year Growth Surge, Upgrades Stock

13 analysts have shared their evaluations of Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $148.15, a high estimate of $187.00, and a low estimate of $122.00. Experiencing a 0.68% decline, the current average is now lower than the previous average price target of $149.17. 
<img src="https://www.benzinga.com/files/images/story/2024/1727794874_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Clorox among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kaumil Gajrawala</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$187.00</td>
<td>$174.00</td>
</tr>
<tr>
<td>Wendy Nicholson</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$170.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$153.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Wendy Nicholson</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$165.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$130.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$153.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$148.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Stephen Powers</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$151.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>Robert Moskow</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Sell</td>
<td>$122.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$150.00</td>
<td>$158.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$122.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Wendy Nicholson</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$145.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Chris Carey</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$130.00</td>
<td>$135.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Clorox. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Clorox compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Clorox's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of Clorox's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CLX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Clorox analyst ratings.</a>
<h2>Unveiling the Story Behind Clorox</h2>
Since its inception more than 100 years ago, Clorox has grown to play in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just less than 85% of Clorox's sales stem from its home turf.
<h3>Clorox's Financial Performance</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Negative Revenue Trend: Examining Clorox's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately -5.75% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Consumer Staples sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Clorox's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 11.35% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Clorox's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 103.1% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Clorox's ROA excels beyond industry benchmarks, reaching 3.74%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 8.85, Clorox adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Ratings For Clorox

Jefferies analyst Kaumil Gajrawala upgrades Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) from Hold to Buy and raises the price target from $174 to $187.

Jefferies Upgrades Clorox to Buy, Raises Price Target to $187

Citigroup analyst Wendy Nicholson maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Neutral and raises the price target from $165 to $170.

Citigroup Maintains Neutral on Clorox, Raises Price Target to $170

DA Davidson analyst Linda Bolton Weiser maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Neutral and maintains $153 price target.

DA Davidson Maintains Neutral on Clorox, Maintains $153 Price Target

To gain an edge, this is what you need to know today.
<figure class="wp-block-image size-large is-resized"><img decoding="async" src="https://thearorareport.com/wp-content/uploads/2024/09/2024-09-05_07h52_00.png" alt="" style="width:624px" /></figure>
<h4 class="wp-block-heading">Jobs Picture</h4>
Please <a href="https://thearorareport.com/chart-analysis-stock-market-jobs-report-mother-of-all-numbers-clx-nvda-mc-09052024">click here</a> for an enlarged chart of Clorox Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) and NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>). CLX chart is in the top pane.&nbsp; NVDA chart is in the bottom pane.
Note the following:
<ul>
<li>This article is about the big picture, not an individual stock.&nbsp; The charts of CLX and NVDA stocks are being used to illustrate the point.</li>
<li>The chart shows that CLX has made significant gains at a time when NVDA has lost market value, including the worst day ever for NVDA when it lost $279B.</li>
<li>The trendline on the chart shows that CLX has moved up smoothly, whereas NVDA has been very volatile.&nbsp; CLX stock is an example of high risk adjusted return, whereas there is high risk in NVDA stock at this time.</li>
<li>As full disclosure, CLX is in the portfolio that surrounds the core Model Portfolio.&nbsp; NVDA is in the core Model Portfolio.&nbsp; Having CLX and NVDA in the portfolio from a risk perspective is an illustration of how to structure a portfolio for high risk adjusted returns to maximize the wealth you generate over your lifetime.</li>
<li>CLX is an example of the cyberhack strategy.&nbsp; The premise behind the cyberhack strategy is that when a company is cyberhacked, and its business suffers, the decline in the stock is often temporary and presents a buying opportunity.&nbsp; CLX stock dropped when it was not able to ship orders due to a cyberhack.&nbsp; As full disclosure, CLX is long from $118.78.</li>
<li>RSI on the chart shows that CLX is overbought.&nbsp; Overbought stocks tend to pullback.&nbsp; Pullbacks are often buying opportunities.&nbsp; As full disclosure, there will be a new signal in The Arora Report&#8217;s ZYX Buy on CLX.</li>
<li>JOLTS jobs report came at 7.67M openings vs. 8.1M consensus.&nbsp; This indicates the jobs picture is weakening.</li>
<li>The Fed's Beige Book indicated that economic activity is stable to declining in most regions of the country.</li>
<li>ADP employment change came at 99K vs. 150K consensus.&nbsp; ADP is the largest private payroll processor in the country.&nbsp; ADP uses its data to give a glimpse of the jobs picture in advance of the official report.
<ul>
<li>In The Arora Report analysis, the ADP report shows that the jobs picture is weakening. The momo crowd is oblivious as usual, but prudent investors need to be aware that the weakening jobs picture leads to a weakening economy.&nbsp; A weakening economy leads to lower earnings.&nbsp; Lower earnings lead to a lower stock market.</li>
</ul>
</li>
<li>Jobless claims came at 227K vs. 236K consensus.&nbsp; This data is running counter to other recent data.&nbsp; However, as we have been stressing, investors should look at the four week moving average and not any one single week.&nbsp; Jobless claims is also a leading indicator and carries heavy weight in The Arora Report models.</li>
<li>ISM Non-Manufacturing Index will be released at 10am ET.&nbsp; The consensus is 51.&nbsp; This data is likely to be market moving if it is far off from the consensus.&nbsp; This is a leading indicator and carries heavy weight in our adaptive <a href="https://thearorareport.com/ALLOCATION%2BMODELS.htm">ZYX Asset Allocation Model</a> with inputs in <a href="https://thearorareport.com/unique-zyx-asset-allocation-4/">ten categories</a>.&nbsp; In plain English, adaptiveness means that the model changes itself with market conditions.&nbsp; Please <a href="https://thearorareport.com/unique-zyx-asset-allocation-3/">click here</a> to see how this is achieved.&nbsp; Most models on Wall Street are static.&nbsp; They work for a while and then stop working when market conditions change.</li>
<li>The jobs report, also known as the mother of all numbers due to its importance, is ahead.&nbsp; It will be released Friday at 8:30am ET.&nbsp; Here are the consensus numbers:
<ul>
<li>Non-farm payrolls of 165K</li>
<li>Non-farm private payrolls of 142K</li>
<li>Average hourly earnings of 0.3%</li>
<li>Unemployment rate of 4.2%</li>
<li>Average work week of 34.3</li>
</ul>
</li>
<li>In The Arora Report analysis, the jobs report will have a major impact on the Fed's decision to cut rates by 25 basis points or 50 basis points.&nbsp; In The Arora Report analysis, here are the current probabilities:
<ul>
<li>75% probability of a 25 basis point cut</li>
<li>25% probability of a 50 basis point cut</li>
</ul>
</li>
<li>In The Arora Report analysis, if the non-farm payrolls are under 100K and the unemployment rate reaches 4.5% or higher, the probability of a 50 basis point rate cut will go up significantly.&nbsp;&nbsp;</li>
<li>In The Arora Report analysis, if the non-farm payrolls are under 100K and the unemployment rate reaches 4.5% or higher, the probability of a stock market correction will go up to 70%.&nbsp;&nbsp;</li>
</ul>
<h4 class="wp-block-heading">Magnificent Seven Money Flows</h4>
In the early trade, money flows are positive in Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).
In the early trade, money flows are negative in Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Alphabet Inc Class C (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>), Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), and NVDA.
In the early trade, money flows are negative in SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>).
<h4 class="wp-block-heading">Momo Crowd And Smart Money In Stocks</h4>
Investors can gain an edge by knowing money flows in SPY and QQQ.  Investors can get a bigger edge by knowing when smart money is buying stocks, gold, and oil.  The most popular ETF for gold is SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>).  The most popular ETF for silver is iShares Silver Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLV#NYSE">SLV</a>).  The most popular ETF for oil is United States Oil ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>).
<h4 class="wp-block-heading">Bitcoin</h4>
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is seeing light selling.
<h4 class="wp-block-heading">Protection Band And What To Do Now</h4>
It is important for investors to look ahead and not in the rearview mirror.
Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider a protection band consisting of cash or Treasury bills or short-term tactical trades as well as short to medium term hedges and short term hedges. This is a good way to protect yourself and participate in the upside at the same time.
You can determine your protection bands by adding cash to hedges.&nbsp; The high band of the protection is appropriate for those who are older or conservative. The low band of the protection is appropriate for those who are younger or aggressive.&nbsp; If you do not hedge, the total cash level should be more than stated above but significantly less than cash plus hedges.
A protection band of 0% would be very bullish and would indicate full investment with 0% in cash.&nbsp; A protection band of 100% would be very bearish and would indicate a need for aggressive protection with cash and hedges or aggressive short selling.
It is worth reminding that you cannot take advantage of new upcoming opportunities if you are not holding enough cash.&nbsp; When adjusting hedge levels, consider adjusting partial stop quantities for stock positions (non ETF); consider using wider stops on remaining quantities and also allowing more room for high beta stocks.&nbsp; High beta stocks are the ones that move more than the market.
<h4 class="wp-block-heading">Traditional 60/40 Portfolio</h4>
Probability based risk reward adjusted for inflation does not favor long duration strategic bond allocation at this time.
Those who want to stick to traditional 60% allocation to stocks and 40% to bonds may consider focusing on only high quality bonds and bonds of five year duration or less.&nbsp; Those willing to bring sophistication to their investing may consider using bond ETFs as tactical positions and not strategic positions at this time.
The Arora Report is known for its accurate calls. The Arora Report correctly called the big artificial intelligence rally before anyone else, the new bull market of 2023, the bear market of 2022, new stock market highs right after the virus low in 2020, the virus drop in 2020, the DJIA rally to 30,000 when it was trading at 16,000, the start of a mega bull market in 2009, and the financial crash of 2008. Please click here to sign up for a free forever <a href="https://thearorareport.com/generate-wealth-newsletter-benzinga">Generate Wealth Newsletter</a>.

Markets

$BTC

AAPL

AMZN

GOOG

MSFT

TSLA

Nvidia Beaten By Clorox, Mother Of All Reports Ahead

August saw the <a href="https://www.benzinga.com/news/earnings/24/08/40648231/wall-street-poised-for-strong-start-as-inflation-data-looms-strategist-says-brace-for-volatile-fall">equity market make good the losses</a> it experienced post its mid-July peak, with earnings and benign data helping the fightback. With August in the rearview mirror, here&#8217;s a look at the leaders and laggards among the S&amp;P 500 Index, a broader gauge of market performance.
3-Part Trend: The month&#8217;s trading could be characterized as a tale of three trends. Stocks extended the weakness into August, with the S&amp;P 500 bottoming on Aug. 5, coinciding with the collapse of the global equity markets. The unwinding of the yen carry trades due to the yen&#8217;s strength perked up risk aversion, sending Japanese stocks into a tailspin, and the reverberations became evident elsewhere.
The S&amp;P 500 Index fell 4.3% intraday on Aug. 5, which happened to be a Monday. The collapse was promptly dubbed Black Monday 2.0 to differentiate it from the Black Monday crash of Oct. 1987. The CBOE Volatility Index, commonly called VIX, more than doubled to 65.73 intraday before pulling back. 
On a positive note, the S&amp;P 500 closed off the lows of the day and was down a more modest 3% by the close.
The market saw a steady recovery from the low through Aug. 22, thanks to a slew of catalysts that reinforced expectations that the Federal Open Market Committee would begin cutting rates at its September meeting.
The strong and rapid recovery pushed traders on the defensive, and the market has been moving sideways since then. 
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="819" height="630" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/31133559/image-325.png" alt="" class="wp-image-524474" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/31133559/image-325.png 819w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/31133559/image-325-300x231.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/31133559/image-325-768x591.png 768w" sizes="(max-width: 819px) 100vw, 819px" /></figure>
Source: Yahoo Finance
For August, the S&amp;P 500 Index gained 2.28%, ending the month at 5,648.40, off its record closing high of 5,667.20 hit on July 16.
See Also: <a href="https://www.benzinga.com/money/best-growth-stocks">Best Growth Stocks Right Now</a>
The Leaders: None of the Magnificent seven stocks, which have been spearheading the broader market uptrend since the start of the 2023, made it to the list of the top 10 gainers. The list featured two cybersecurity companies, namely CrowdStrike Holdings, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) and Fortinet, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>). CrowdStrike was rebounding from its global-outage-induced slump seen since July 19. 
Fortinet was helped by a strong post-earnings rally.
Two household and personal care products companies also made the cut, while a management change did the truck for coffee chain Starbucks Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>).
The top 10 gainers for the month are:
<ul>
<li>Packaged food company Kellanova&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/K#NYSE">K</a>) (+38.62%) (upside primarily due to the rumors of a buyout by privately-held Mars and the subsequent confirmation of the deal)</li>
<li>Fortinet (+32.17%)</li>
<li>Starbucks (+26.52%)</li>
<li>Axon Enterprise, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) (+21.65%); Much of the gains stemmed from a post-earnings bump seen on Aug.7)</li>
<li>Clorox Company&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) (+21.02%)</li>
<li>CrowdStrike (+19.54%)</li>
<li>Kenvue Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>) (+19.88%)</li>
<li>Best Buy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) (+16.04%)</li>
<li>Arch Capital Group Ltd.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACGL#NYSE">ACGL</a>) (+18.07%)</li>
<li>Progressive Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) (+17.78%)</li>
</ul>
The Laggards: Artificial intelligence server manufacturer Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>), which had a dream run after its inclusion in the S&amp;P 500 Index, plummeted following a short report and the delay flagged by the company in filing its 10-K report. Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>), which is fraught with fundamental risk, was also one of the worst performers for the month.
A few retailers ended up in the list of the top 10 S&amp;P 500 decliners for August.
The top 10 losers for the month are:
<ul>
<li>Super Micro (-37.62%)</li>
<li>Moderna, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) (-35.08%)</li>
<li>Dollar General Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) (-31.08%)</li>
<li>Intel (-27.86%)</li>
<li>Walgreens Boots Alliance, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) (-20.19%)</li>
<li>Dollar Tree, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) (-19.02%)</li>
<li>Charles River Laboratories International, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) (-18.99%)</li>
<li>Airbnb, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) (-15.94)</li>
<li>Bath &amp; Body Works, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) (-15.80%)</li>
<li>Etsy, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) (-15.43%)</li>
</ul>
Earnings reactions triggered the weakness seen in some of these stocks, including Intel, and <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40139012/moderna-stock-trading-lower-on-dismal-guidance-analysts-cuts-price-targets-noting-c">Moderna, which reduced its full-year forecast.</a>
With the Fed all but decided on a September rate cut, some of these beaten-down stocks, especially those in the retail space, could stage a turnaround. 
The SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), an exchange-traded fund that tracks the S&amp;P 500 Index, ended Friday&#8217;s session up 0.95% at $563.68, according to <a href="https://benzinga.grsm.io/register174">Benzinga Pro data.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40594093/economist-peter-schiff-warns-fed-may-be-committing-mistake-by-lowering-rates-in-sep">Economist Peter Schiff Warns Fed May Be Committing Mistake By Lowering Rates In September As Dollar Index Falls To Lowest In Over A Year</a></li>
</ul>

ABNB

ACGL

AXON

BBWI

CRWD

DLTR

ETSY

FTNT

GDDY

INTC

KVUE

MPWR

MRNA

SBUX

SMCI

UBER

Magnificent 7 Miss Out, 2 Cybersecurity Stocks Stand Firm, Retailers Lag In Volatile August: Here Are The Top S&P 500 Gainers And Losers

Throughout the last three months, 11 analysts have evaluated Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Clorox and provided 12-month price targets. The average target is $140.55, accompanied by a high estimate of $165.00 and a low estimate of $122.00. A 2.54% drop is evident in the current average compared to the previous average price target of $144.22. 
<img src="https://www.benzinga.com/files/images/story/2024/1724875267_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Clorox by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wendy Nicholson</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$165.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$130.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$153.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$148.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Stephen Powers</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$151.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>Robert Moskow</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Sell</td>
<td>$122.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$150.00</td>
<td>$158.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$122.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Wendy Nicholson</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$145.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Chris Carey</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$130.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Kevin Grundy</td>
<td>Exane BNP Paribas</td>
<td>Announces</td>
<td>Underperform</td>
<td>$130.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Clorox. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Clorox compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Clorox's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Clorox's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CLX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Clorox analyst ratings.</a>
<h2>Get to Know Clorox Better</h2>
Since its inception more than 100 years ago, Clorox has grown to play in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just less than 85% of Clorox's sales stem from its home turf.
<h3>Financial Milestones: Clorox's Journey</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Clorox's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately -5.75% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Staples sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 11.35%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Clorox's ROE excels beyond industry benchmarks, reaching 103.1%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 3.74%, the company showcases effective utilization of assets.
Debt Management: Clorox's debt-to-equity ratio is below the industry average at 8.85, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Evaluating Clorox: Insights From 11 Financial Analysts

Citigroup analyst Wendy Nicholson maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Neutral and raises the price target from $145 to $165.

Citigroup Maintains Neutral on Clorox, Raises Price Target to $165

Jim Cramer recommended buying The Clorox Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) on the latest edition of CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>.&#8221; 
&#8220;[Clorox CEO] Linda Rendle has done a remarkable job, let's understand that. She did not get a good hand,&#8221; Cramer said. &#8220;She was not <a href="https://www.benzinga.com/news/earnings/24/08/40118794/clorox-stock-climbs-after-q2-results-strong-forward-guidance">delivered a good hand.&#8221;</a>
On Aug. 1, Clorox reported quarterly earnings of $1.82 per share which beat the analyst consensus estimate of $1.56. Quarterly sales clocked in at $1.903 billion, missing the analyst consensus estimate by 2.46%.
See Also: <a href="https://www.benzinga.com/sec/insider-trades/0001682880/linda-j-rendle">Linda Rendle&#8217;s Estimated Net Worth</a>
When asked about GLOBALFOUNDRIES Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>), he said, &#8220;I don't like the foundry business as much. It turns out that the only people who really know how to make them cheaply is Taiwan Semi. So if you want to own a foundry, Taiwan Semi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) is the one to do it.&#8221;
On Aug. 6, GlobalFoundries reported a fiscal second-quarter 2024 revenue decline of 12% year-on-year to $1.63 billion, beating the analyst consensus estimate of $1.62 billion.
SentinelOne, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) is &#8220;picking up some business, so therefore I'm going to tell you that I actually support it for, only for a trade,&#8221; Cramer said.
SentinelOne will release financial results for its fiscal second quarter 2025, after the closing bell on Tuesday, Aug. 27.
The &#8220;Mad Money&#8221; host said he is not recommending any airlines, when asked about Delta Air Lines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>).
Delta Air, last week, disclosed that it expects the latest operational disruptions resulting from the outage incident to have a direct revenue impact of $380 million for the September quarter due to flight cancellations and customer compensation in cash and SkyMiles.
Cramer said Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) is his &#8220;least favorite of the Mag Seven,&#8221; as they don't run the company well.
Alphabet shares closed lower on Wednesday following a report suggesting a bid to break up Google is one of the options being considered by the Justice Department.
When asked about Ferrari N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RACE#NYSE">RACE</a>), he said, &#8220;Take out your cost basis and let the rest run.&#8221;
On Aug. 1, Ferrari reported earnings of $2.47 per share on quarterly revenue of $1.84 billion, beating estimates on both the top and bottom line.
Price Action:
<ul>
<li>GLOBALFOUNDRIES shares fell 2.9% to settle at $43.56 on Wednesday.</li>
<li>Sentinel shares rose 2% to close at $22.79.</li>
<li>Clorox shares gained 1.5% to settle at $144.52 on Wednesday.</li>
<li>Delta shares fell 2.1% to close at $38.69.</li>
<li>Alphabet shares fell 2.3% to close at $160.37 on Wednesday.</li>
<li>Ferrari shares gained 4.9% to settle at $452.90 on Wednesday.</li>
</ul>
Read Next: 
<ul>
<li>J<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40368892/jim-cramer-avoid-middle-market-plays-like-golub-capital-buy-mueller-industries-it-is-fan">im Cramer: &#8216;Avoid Middle Market Plays&#8217; Like Golub Capital, Buy Mueller Industries — &#8216;It Is Fantastic&#8217;</a></li>
</ul>

Long Ideas

Media

GOOGL

RACE

Jim Cramer Recommends Buying Clorox: 'CEO Has Done Remarkable Job'

Barclays analyst Lauren Lieberman maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Underweight and raises the price target from $122 to $130.

Barclays Maintains Underweight on Clorox, Raises Price Target to $130

DA Davidson analyst Linda Bolton Weiser maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Neutral and lowers the price target from $162 to $153.

DA Davidson Maintains Neutral on Clorox, Lowers Price Target to $153

JP Morgan analyst Andrea Teixeira maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Neutral and lowers the price target from $150 to $148.

JP Morgan Maintains Neutral on Clorox, Lowers Price Target to $148

Deutsche Bank analyst Stephen Powers maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Hold and raises the price target from $144 to $151.

Deutsche Bank Maintains Hold on Clorox, Raises Price Target to $151

U.S. stocks were lower, with the Dow Jones index falling over 900 points on Friday.
Shares of MercadoLibre, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) rose sharply during Friday's session after the company reported better-than-expected quarterly financial results.
Mercado Libre reported net revenue of $5.07 billion in the second quarter, up 42% year-over-year. The revenue beat a Street consensus estimate of $4.68 billion, according to data from Benzinga Pro.
The company reported a 36% year-over-year increase in total payment volume for the second quarter and a 20% year-over-year rise in gross merchandise volume. Earnings per share were $10.48 in the second quarter, beating a Street consensus estimate of $8.43.
MercadoLibre shares jumped 9.6% to $1,760.79 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Fitell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEL#NASDAQ">FTEL</a>) gained 26% to $24.50.</li>
<li>Tandem Diabetes Care, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) shares surged 23.6% to $43.52 in pre-market trading following better-than-expected second-quarter earnings and strong guidance.</li>
<li>Cerus Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) gained 23% to $2.5200  after the company reported better-than-expected second-quarter EPS results and raised its FY24 product revenue guidance above estimates..</li>
<li>Integral Ad Science Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAS#NASDAQ">IAS</a>) shares gained 14.9% to $11.38 after the company reported better-than-expected quarterly financial results and issued FY24 revenue guidance above estimates.</li>
<li>Willdan Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLDN#NASDAQ">WLDN</a>) climbed 10.1% to $36.52 after the company reported better-than-expected second-quarter financial results.</li>
<li>Fresh Del Monte Produce Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDP#NYSE">FDP</a>) gained 8.6% to $26.73 following better-than-expected earnings.</li>
<li>ICF International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICFI#NASDAQ">ICFI</a>) rose 8.3% to $158.06 following upbeat quarterly results.</li>
<li>EZCORP, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>) jumped 8.2% to $11.35.</li>
<li>Standard BioTools Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAB#NYSE">LAB</a>) gained 7.7% to $1.530.</li>
<li>Bright Horizons Family Solutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFAM#NYSE">BFAM</a>) gained 7.5% to $127.32 following strong quarterly results.</li>
<li>DoorDash, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) rose 6.7% to $115.52 as the company posted upbeat earnings.</li>
<li>GoDaddy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDDY#NYSE">GDDY</a>) jumped 5.8% to $149.66 after the company reported better-than-expected second-quarter sales results..</li>
<li>The Clorox Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) gained 4.3% to $139.94 after the company reported better-than-expected fourth-quarter adjusted EPS results and issued FY24 adjusted EPS guidance above estimates.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/08/40131885/dow-dips-over-400-points-apple-posts-upbeat-earnings">Dow Dips Over 400 Points; Apple Posts Upbeat Earnings</a></li>
</ul>

Intraday Update

BFAM

CERS

DASH

EZPW

FTEL

ICFI

MELI

TNDM

WLDN

MercadoLibre Posts Upbeat Results, Joins Integral Ad Science, Willdan Group, Fresh Del Monte Produce And Other Big Stocks Moving Higher On Friday

WIIM

Clorox shares are trading higher after the company reported better-than-expected Q4 adjusted EPS results and issued FY24 adjusted EPS guidance above estimates.

Clorox Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) shares are up after the company reported its second-quarter financial results Thursday. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/08/n40114127/clorox-reports-q4-and-fy24-results-provides-fy25-outlook">key figures from the report. </a>
The Details: Clorox reported quarterly earnings of $1.82 per share which beat the analyst consensus estimate of $1.56 by 16.67%. Quarterly sales clocked in at $1.903 billion, missing the analyst consensus estimate by 2.46% and representing a 5.75% decrease from the same period last year. 
Clorox said the net sales decreased was driven largely by the impacts of the Argentina divestiture, unfavorable price mix and lower volume.
Read Also: <a href="https://www.benzinga.com/news/earnings/24/08/40105885/ferrari-shares-race-higher-on-strong-q2-results">Ferrari Shares Race Higher On Strong Q2 Results</a>
&#8220;We closed out the fiscal year with strong margin expansion and double-digit adjusted EPS growth despite substantial disruption and consumption loss from the cyberattack,&#8221; said Clorox CEO Linda Rendle.
&#8220;While fully restoring supply and distribution, as well as recovering nearly all of our market share, we remained relentless in driving our IGNITE strategy forward. We made strong progress as we evolved our portfolio to accelerate profitable growth, completed the implementation of our streamlined operating model and advanced our digital transformation.&#8221;
Outlook:&nbsp;Clorox sees fiscal year earnings between $6.55 and $6.80 per share, versus the $6.45 estimate.
CLX Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Clorox shares are up 4.37% after-hours at $140 at the time of publication Thursday.
Read Next:
<ul>
<li>&nbsp;<a href="https://www.benzinga.com/news/24/08/40112573/the-bear-cave-issues-report-on-taskus-what-to-know">The Bear Cave Issues Report On TaskUs: What To Know</a></li>
</ul>
Image: Gerd Altmann from Pixabay

After-Hours Center

Clorox Stock Climbs After Q2 Results, Strong Forward Guidance

How is VOO stock faring? The Vanguard S&P 500 ETF is up 2.76% in the past five days and has risen 28.11% over the past year. According to TipRanks'...

VOO ETF Update, 9/16/2024

How is SPY stock faring? The SPDR S&P 500 ETF Trust is up 1.41% in the past five days and has risen 28.01% over the past year. According to TipRank...

SPY ETF Update, 9/17/2024

Clorox declares $1.22 dividend

How is VOO stock faring? The Vanguard S&P 500 ETF&nbsp;has been almost flat over the past five days but has risen about 19% over the past year. Acc...

VOO ETF Update, 9/19/2024

In a report released yesterday, Christopher Carey from Wells Fargo assigned a Sell rating to Clorox (CLX – Research Report), with a price target of...

Wells Fargo Issues a Sell Rating on Clorox (CLX)

Clorox entering FY25 as 'a different company' -- analyst

Consumer staples with lowest quant rating are worst performers in Q3: DLTR, DG, LW

Goldman Sachs analyst Bonnie Herzog has maintained their bearish stance on CLX stock, giving a Sell rating on September 23. Bonnie Herzog has given...

Sell Rating on Clorox Amid Anticipated Sales Decline and Overvaluation Concerns

In a report released yesterday, Christopher Carey from Wells Fargo maintained a Sell rating on Clorox (CLX – Research Report), with a price target ...

Clorox (CLX) Gets a Sell from Wells Fargo

Goldman sees a 'relief rally' potential for these option calls ahead of earnings

ALLE

COST

CTAS

DXCM

FSTA

MDLZ

SOLV

XLRE

Press Releases

Clorox Announces Aug. 1 Webcast of Fourth-Quarter and Fiscal Year 2024 Results

Glad® and T-Boz Bring '90s Nostalgia to the Household Cleaning Experience

Dividends

Clorox Increases Quarterly Dividend to $1.22 Per Share

Clorox Reports Q4 and FY24 Results, Provides FY25 Outlook

CloroxPro Introduces New, Plant-Based Clorox EcoClean Disinfecting Wipes

Clorox to Present at Barclays Global Consumer Staples Conference

Clorox Completes Previously Announced Divestiture of its Better Health VMS Business

Clorox Declares Regular Quarterly Dividend of $1.22 Per Share

EPA Names Clorox as 2024 Safer Choice Partner of the Year for Advancing Ingredient and Product Safety

Comments

Clorox

Actualités

Dernières nouvelles pour Clorox (NYSE:CLX) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL